GlassScriptPhysician profile
Ahmed Munir
NPI 1154874881
$3,858.56
in general payments reported to CMS, 2019-2025
12 companies · $3,157 in 2025
The $3,157 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $219 · 2024: $367 · 2025: $3,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,517 · Travel and Lodging: $1,240 · Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,517.38 |
| Travel and Lodging | $1,240.22 |
| Food and Beverage | $985.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,839.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $392.44 | 2022-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $253.51 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $109.58 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $71.71 | 2023-2024 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $67.30 | 2025 | |
| Edwards Lifesciences Corporation | $32.60 | 2024 | Sapien 3 Ultra Resilia |
| United Therapeutics Corporation | $24.86 | 2024 | Tyvaso |
| Viatris Specialty LLC | $18.28 | 2025 | Yupelri |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Electromed, INC. | $15.73 | 2023 | Smartvest |
| Pfizer INC. | $15.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.